Novozymes A/S
CSE:NZYM B

Watchlist Manager
Novozymes A/S Logo
Novozymes A/S
CSE:NZYM B
Watchlist
Price: 403 DKK -3.93% Market Closed
Market Cap: 165.6B DKK
Have any thoughts about
Novozymes A/S?
Write Note

Novozymes A/S
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novozymes A/S
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Novozymes A/S
CSE:NZYM B
Cash Equivalents
kr1.1B
CAGR 3-Years
-2%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Chr Hansen Holding A/S
CSE:CHR
Cash Equivalents
€56m
CAGR 3-Years
-17%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
P
Photocat A/S
STO:PCAT
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novozymes A/S
Glance View

Market Cap
165.6B DKK
Industry
Chemicals

Novozymes A/S is a global leader in biotechnology, focusing on the production of enzymes and microorganisms that enhance industrial processes. Founded in 1925 and based in Denmark, the company has consistently leveraged its deep scientific expertise to innovate solutions across various sectors, including agriculture, bioenergy, and food & beverage. By developing sustainable alternatives to traditional chemical processes, Novozymes not only improves efficiency for its clients but also helps minimize environmental impact. As industries continue to shift towards greener practices, Novozymes stands at the forefront of this transition, positioning itself as a pivotal player committed to driving sustainable development. For investors, Novozymes represents a compelling opportunity in a growing market driven by increasing awareness of sustainability and resource efficiency. The company boasts a diverse portfolio of products and a strong track record of profitability, sustained by its continuous investment in research and development. With a robust customer base spanning across more than 30 industries, Novozymes is well-equipped to capitalize on the expanding demand for bio-based solutions. Investors can find confidence in Novozymes' strategic focus on innovation and its ability to adapt to the evolving landscape of global sustainability goals, making it a strong candidate for those looking to invest in a future-oriented enterprise.

NZYM B Intrinsic Value
124.85 DKK
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Novozymes A/S's Cash Equivalents?
Cash Equivalents
1.1B DKK

Based on the financial report for Dec 31, 2023, Novozymes A/S's Cash Equivalents amounts to 1.1B DKK.

What is Novozymes A/S's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
9%

Over the last year, the Cash Equivalents growth was 7%. The average annual Cash Equivalents growth rates for Novozymes A/S have been -2% over the past three years , 9% over the past five years .

Back to Top